CoChat
Sign Up
Cited by 32Traditional Chinese Medicine AnalysisAutophagy in Disease and TherapyNatural Compounds in Disease Treatment

Recent advances of tanshinone in regulating autophagy for medicinal research

Open access
Wu, Sha, Zhao, Kui, Wang, Jie, Liu, Nannan, Nie, Kaidi, Qi, Luming, Xia, Lina·2023·Frontiers in Pharmacology
DOI 10.3389/fphar.2022.1059360PMC PMC9877309
Open this paper in CoChat — free accountOpen PDF

Abstract

Initially described as an ancient and highly conserved catabolic biofunction, autophagy plays a significant role in disease pathogenesis and progression. As the bioactive ingredient of Salvia miltiorrhiza, tanshinone has recently shown profound effects in alleviating and treating various diseases by regulating autophagy. However, compared to the remarkable achievements in the known pharmacological effects of this traditional Chinese medicine, there is a lack of a concise and comprehensive review deciphering the mechanism by which tanshinone regulates autophagy for medicinal research. In this context, we concisely review the advances of tanshinone in regulating autophagy for medicinal research, including human cancer, the nervous system, and cardiovascular diseases. The pharmacological effects of tanshinone targeting autophagy involve the regulation of autophagy-related proteins, such as Beclin-1, LC3-II, P62, ULK1, Bax, ATG3, ATG5, ATG7, ATG9, and ATG12; the regulation of the PI3K/Akt/mTOR, MEK/ERK/mTOR, Beclin-1-related, and AMPK-related signaling pathways; the accumulation of reactive oxygen species (ROS); and the activation of AMPK. Notably, we found that tanshinone played a dual role in human cancers in an autophagic manner, which may provide a new avenue for potential clinical application. In brief, these findings on autophagic tanshinone and its derivatives provide a new clue for expediting medicinal research related to tanshinone compounds and autophagy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.1059360

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Efferocytosis plays a crucial role in maintaining tissue homeostasis and in modulating immune responses.

    “Efferocytosis, the process by which macrophages engulf and remove apoptotic cells (ACs), plays a crucial role in maintaining tissue homeostasis and in modulating immune responses.”

    From Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer (2026) · cites this paper as [6]

    The cardiovascular-disease table mentions “repairing efferocytosis and M2 phenotype” in a tanshinone-treated atherosclerosis model, but does not explain efferocytosis’s role in tissue homeostasis or immune responses. Searches for macrophage clearance of apoptotic cells and immune regulation found no passage in our copy addressing the attributed claim. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 120

  1. Amaravadi R. K. Kimmelman A. C. Debnath J. (2019). Targeting autophagy in cancer: Recent advances and future directions. Cancer Discov. 9 (9), 1167– 1181. 10.1158/2159-8290.Cd-19-0292 31434711 PMC7306856 · DOI · Paper page
  2. Aminu N. Bello I. Umar N. M. Tanko N. Aminu A. Audu M. M. (2020). The influence of nanoparticulate drug delivery systems in drug therapy. J. Drug Deliv. Sci. Technol. 60, 101961. 10.1016/j.jddst.2020.101961 · DOI
  3. Ansari M. A. Khan F. B. Safdari H. A. Almatroudi A. Alzohairy M. A. Safdari M. (2021). Prospective therapeutic potential of Tanshinone IIA: An updated overview. Pharmacol. Res. 164, 105364. 10.1016/j.phrs.2020.105364 33285229 · DOI
  4. Atanasov A. G. Zotchev S. B. Dirsch V. M. Supuran C. T. Int Nat Prod Sci T. (2021). Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 20 (3), 200– 216. 10.1038/s41573-020-00114-z 33510482 PMC7841765 · DOI
  5. Bao Y. R. Chen J. W. Jiang Y. Wang L. H. Xue R. Qian J. X. (2020). Sodium tanshinone II sulfonate A ameliorates hypoxia-induced pulmonary hypertension. Front. Pharmacol. 11, 687. 10.3389/fphar.2020.00687 32508639 PMC7253651 · DOI
  6. Basatemur G. L. Jorgensen H. F. Clarke M. C. H. Bennett M. R. Mallat Z. (2019). Vascular smooth muscle cells in atherosclerosis. Nat. Rev. Cardiol. 16 (12), 727– 744. 10.1038/s41569-019-0227-9 31243391 · DOI · Paper page
  7. Baselga J. Im S. A. Iwata H. Cortés J. De Laurentiis M. Jiang Z. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18 (7), 904– 916. 10.1016/S1470-2045(17)30376-5 28576675 PMC5549667 · DOI
  8. Caesar L. K. Cech N. B. (2019). Synergy and antagonism in natural product extracts: When 1+1 does not equal 2. Nat. Prod. Rep. 36 (6), 869– 888. 10.1039/c9np00011a 31187844 PMC6820002 · DOI
  9. Castel P. Toska E. Engelman J. A. Scaltriti M. (2021). The present and future of PI3K inhibitors for cancer therapy. Nat. Cancer 2 (6), 587– 597. 10.1038/s43018-021-00218-4 35118422 PMC8809509 · DOI
  10. Chen P. An Q. Huang Y. Zhang M. Mao S. (2021). Prevention of endotoxin-induced cardiomyopathy using sodium tanshinone IIA sulfonate: Involvement of augmented autophagy and NLRP3 inflammasome suppression. Eur. J. Pharmacol. 909, 174438. 10.1016/j.ejphar.2021.174438 34437885 · DOI
  11. Chen W. Li X. Guo S. Song N. Wang J. Jia L. (2019). Tanshinone IIA harmonizes the crosstalk of autophagy and polarization in macrophages via miR-375/KLF4 pathway to attenuate atherosclerosis. Int. Immunopharmacol. 70, 486– 497. 10.1016/j.intimp.2019.02.054 30870679 · DOI
  12. Chen W. Ma Z. Yu L. Mao X. Ma N. Guo X. (2022). Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation. Exp. Mol. Med. 54, 1536– 1548. 10.1038/s12276-022-00780-6 36123535 PMC9535011 · DOI
  13. Chen X. Guo J. Bao J. Lu J. Wang Y. (2014). The anticancer properties of Salvia miltiorrhiza bunge (danshen): A systematic review. Med. Res. Rev. 34 (4), 768– 794. 10.1002/med.21304 24123144 · DOI
  14. Deng C. Zhao L. Yang Z. Shang J. J. Wang C. Y. Shen M. Z. (2022). Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury. Acta Pharmacol. Sin. 43 (3), 520– 528. 10.1038/s41401-021-00676-7 34040166 PMC8888646 · DOI
  15. Ding L. Wang S. Qu X. Wang J. (2016). Tanshinone IIA sensitizes oral squamous cell carcinoma to radiation due to an enhanced autophagy. Environ. Toxicol. Pharmacol. 46, 264– 269. 10.1016/j.etap.2016.07.021 27521571 · DOI
  16. Ding L. Wang S. Wang W. Lv P. Zhao D. Chen F. (2017). Tanshinone IIA affects autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway. Pharmacology 99 (3-4), 188– 195. 10.1159/000452340 27889779 · DOI
  17. Dreyling M. Santoro A. Mollica L. Leppä S. Follows G. A. Lenz G. (2017). Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 35 (35), 3898– 3905. 10.1200/JCO.2017.75.4648 28976790 · DOI
  18. Dutta S. Mahalanobish S. Saha S. Ghosh S. Sil P. C. (2019). Natural products: An upcoming therapeutic approach to cancer. Food Chem. Toxicol. 128, 240– 255. 10.1016/j.fct.2019.04.012 30991130 · DOI
  19. El-Khider F. McDonald C. (2016). Links of autophagy dysfunction to inflammatory bowel disease onset. Dig. Dis. 34 (1-2), 27– 34. 10.1159/000442921 PMC5378153 26982478 · DOI
  20. Elmenier F. M. Lasheen D. S. Abouzid K. A. M. (2019). Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur. J. Med. Chem. 183, 111718. 10.1016/j.ejmech.2019.111718 31581005 · DOI
  21. Fan L. Mao C. Hu X. Zhang S. Yang Z. Hu Z. (2020). New insights into the pathogenesis of Alzheimer's disease. Front. Neurol. 10, 1312. 10.3389/fneur.2019.01312 31998208 PMC6965067 · DOI
  22. Fan X. Y. Tian C. Wang H. Xu Y. Ren K. Zhang B. Y. (2015). Activation of the AMPK-ULK1 pathway plays an important role in autophagy during prion infection. Sci. Rep. 5, 14728. 10.1038/srep14728 26423766 PMC4589734 · DOI
  23. Fang Z. Y. Zhang M. Liu J. N. Zhao X. Zhang Y. Q. Fang L. (2021). Tanshinone IIA: A review of its anticancer effects. Front. Pharmacol. 11, 611087. 10.3389/fphar.2020.611087 33597880 PMC7883641 · DOI
  24. Faubert B. Vincent E. E. Poffenberger M. C. Jones R. G. (2015). The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Lett. 356 (2), 165– 170. 10.1016/j.canlet.2014.01.018 24486219 · DOI
  25. Filomeni G. De Zio D. Cecconi F. (2015). Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell. Death Differ. 22 (3), 377– 388. 10.1038/cdd.2014.150 25257172 PMC4326572 · DOI · Paper page
  26. Fleckenstein M. Keenan T. D. L. Guymer R. H. Chakravarthy U. Schmitz-Valckenberg S. Klaver C. C. (2021). Age-related macular degeneration. Nat. Rev. Dis. Prim. 7 (1), 31. 10.1038/s41572-021-00265-2 33958600 PMC12878645 · DOI
  27. Flinn I. W. Hillmen P. Montillo M. Nagy Z. Illés Á. Etienne G. (2018). The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 132 (23), 2446– 2455. 10.1182/blood-2018-05-850461 30287523 PMC6284216 · DOI
  28. Fu X. Zhao W. Li K. Zhou J. Chen X. (2021). Cryptotanshinone inhibits the growth of HCT116 colorectal cancer cells through endoplasmic reticulum stress-mediated autophagy. Front. Pharmacol. 12, 653232. 10.3389/fphar.2021.653232 34220498 PMC8248532 · DOI
  29. Furman R. R. Sharman J. P. Coutre S. E. Cheson B. D. Pagel J. M. Hillmen P. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370 (11), 997– 1007. 10.1056/NEJMoa1315226 24450857 PMC4161365 · DOI
  30. Gao H. Sun W. Zhao W. Hao W. Leung C. H. Lu J. (2015). Total tanshinones-induced apoptosis and autophagy via reactive oxygen species in lung cancer 95D cells. Am. J. Chin. Med. 43 (6), 1265– 1279. 10.1142/s0192415x1550072x 26394653 · DOI
  31. Gao S. Liu Z. Li H. Little P. J. Liu P. Xu S. (2012). Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220 (1), 3– 10. 10.1016/j.atherosclerosis.2011.06.041 21774934 · DOI · Paper page
  32. Geuna E. Milani A. Martinello R. Aversa C. Valabrega G. Scaltriti M. (2015). Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. Expert Opin. Invest. Drugs 24 (3), 421– 431. 10.1517/13543784.2015.1008132 25645727 · DOI
  33. Goswami S. K. Ranjan P. Dutta R. K. Verma S. K. (2021). Management of inflammation in cardiovascular diseases. Pharmacol. Res. 173, 105912. 10.1016/j.phrs.2021.105912 34562603 PMC8541927 · DOI
  34. Guo S. Luo W. Liu L. Pang X. Zhu H. Liu A. (2016). Isocryptotanshinone, a STAT3 inhibitor, induces apoptosis and pro-death autophagy in A549 lung cancer cells. J. Drug Target. 24 (10), 934– 942. 10.3109/1061186x.2016.1157882 26904961 · DOI
  35. Han D. Wu X. Liu L. Shu W. Huang Z. (2018). Sodium tanshinone IIA sulfonate protects ARPE-19 cells against oxidative stress by inhibiting autophagy and apoptosis. Sci. Rep. 8, 15137. 10.1038/s41598-018-33552-2 30310136 PMC6181947 · DOI
  36. Hsieh Y. C. Tsou P. Y. Wang Y. H. Chao C. C. T. Lee W. C. Lee M. T. G. (2020). Risk factors for myocardial infarction and stroke among sepsis survivors: A competing risks analysis. J. Intensive Care Med. 35 (1), 34– 41. 10.1177/0885066619844936 31079522 · DOI
  37. Hua H. Kong Q. Zhang H. Wang J. Luo T. Jiang Y. (2019). Targeting mTOR for cancer therapy. J. Hematol. Oncol. 12 (1), 71. 10.1186/s13045-019-0754-1 31277692 PMC6612215 · DOI
  38. Jian S. Liang C. Lian M. Che H. Tang R. Fan X. (2020). Tanshinone I induces apoptosis and protective autophagy in human glioblastoma cells via a reactive oxygen species-dependent pathway. Int. J. Mol. Med. 45 (4), 983– 992. 10.3892/ijmm.2020.4499 32124953 PMC7053869 · DOI
  39. Jing X. Xu Y. Cheng W. Guo S. Zou Y. He L. (2016). Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers. Cancer Chemother. Pharmacol. 77 (6), 1171– 1181. 10.1007/s00280-016-3034-6 27100736 · DOI
  40. Ju Y. Tam K. Y. (2022). Pathological mechanisms and therapeutic strategies for Alzheimer's disease. Neural Regen. Res. 17 (3), 543– 549. 10.4103/1673-5374.320970 34380884 PMC8504384 · DOI
  41. Jung C. H. Ro S. H. Cao J. Otto N. M. Kim D. H. (2010). mTOR regulation of autophagy. FEBS Lett. 584 (7), 1287– 1295. 10.1016/j.febslet.2010.01.017 20083114 PMC2846630 · DOI · Paper page
  42. Juric D. Janku F. Rodón J. Burris H. A. Mayer I. A. Schuler M. (2019). Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial. JAMA Oncol. 5 (2), e184475. 10.1001/jamaoncol.2018.4475 30543347 PMC6439561 · DOI
  43. Juric D. Rodon J. Tabernero J. Janku F. Burris H. A. Schellens J. H. M. (2018). Phosphatidylinositol 3-kinase α–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study. J. Clin. Oncol. 36 (13), 1291– 1299. 10.1200/JCO.2017.72.7107 29401002 PMC5920739 · DOI
  44. Kaarniranta K. Uusitalo H. Blasiak J. Felszeghy S. Kannan R. Kauppinen A. (2020). Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog. Retin. Eye Res. 79, 100858. 10.1016/j.preteyeres.2020.100858 32298788 PMC7650008 · DOI
  45. Kauppinen A. Paterno J. J. Blasiak J. Salminen A. Kaarniranta K. (2016). Inflammation and its role in age-related macular degeneration. Cell. Mol. Life Sci. 73 (9), 1765– 1786. 10.1007/s00018-016-2147-8 26852158 PMC4819943 · DOI
  46. Kim K. H. Lee M. S. (2014). Autophagy-a key player in cellular and body metabolism. Nat. Rev. Endocrinol. 10 (6), 322– 337. 10.1038/nrendo.2014.35 24663220 · DOI
  47. Lampson B. L. Brown J. R. (2017). PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin. Invest. Drugs 26 (11), 1267– 1279. 10.1080/13543784.2017.1384815 PMC5747968 28945111 · DOI
  48. Lee J. Sohn E. J. Yoon S. Won G. Kim C. G. Jung J. H. (2017). Activation of JNK and IRE1 is critically involved in tanshinone I-induced p62 dependent autophagy in malignant pleural mesothelioma cells: Implication of p62 UBA domain. Oncotarget 8 (15), 25032– 25045. 10.18632/oncotarget.15336 28212571 PMC5421907 · DOI
  49. Li C. Han X. Zhang H. Wu J. Li B. (2016). The interplay between autophagy and apoptosis induced by tanshinone IIA in prostate cancer cells. Tumor Biol. 37 (6), 7667– 7674. 10.1007/s13277-015-4602-9 26687918 · DOI
  50. Li Q. Liu Y. Sun M. (2017a). Autophagy and Alzheimer's disease. Cell. Mol. Neurobiol. 37 (3), 377– 388. 10.1007/s10571-016-0386-8 27260250 PMC11482122 · DOI
  51. Li X. He S. Ma B. (2020). Autophagy and autophagy-related proteins in cancer. Mol. Cancer 19 (1), 12. 10.1186/s12943-020-1138-4 31969156 PMC6975070 · DOI
  52. Li X. Li Z. Li X. Liu B. Liu Z. (2017b). Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell. BMC Cancer 17, 357. 10.1186/s12885-017-3329-y 28532456 PMC5441012 · DOI
  53. Li Z. M. Xu S. W. Liu P. Q. (2018). Salvia miltiorrhiza burge (danshen): A golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol. Sin. 39 (5), 802– 824. 10.1038/aps.2017.193 29698387 PMC5943903 · DOI
  54. Li Z. Wang C. Wang Z. Zhu C. Li J. Sha T. (2019). Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature 575 (7781), 203– 209. 10.1038/s41586-019-1722-1 31666698 · DOI · Paper page
  55. Liang Xiao H. Kleeman Linda K. Jiang Hui H. Gordon G. Goldman James E. Berry G. (1998). Protection against fatal sindbis virus encephalitis by Beclin, a novel bcl-2-interacting protein. J. Virol. 72 (11), 8586– 8596. 10.1128/JVI.72.11.8586-8596.1998 9765397 PMC110269 · DOI
  56. Libby P. (2021). The changing landscape of atherosclerosis. Nature 592 (7855), 524– 533. 10.1038/s41586-021-03392-8 33883728 · DOI · Paper page
  57. Limpert A. S. Lambert L. J. Bakas N. A. Bata N. Brun S. N. Shaw R. J. (2018). Autophagy in cancer: Regulation by small molecules. Trends Pharmacol. Sci. 39 (12), 1021– 1032. 10.1016/j.tips.2018.10.004 30454769 PMC6349222 · DOI
  58. Liu X. Liu J. (2020). Tanshinone I induces cell apoptosis by reactive oxygen species-mediated endoplasmic reticulum stress and by suppressing p53/DRAM-mediated autophagy in human hepatocellular carcinoma. Artif. Cells, Nanomed., Biotechnol. 48 (1), 488– 497. 10.1080/21691401.2019.1709862 32013613 · DOI
  59. Lu J. Shan J. Liu N. Ding Y. Wang P. (2019a). Tanshinone IIA can inhibit angiotensin II-induced proliferation and autophagy of vascular smooth muscle cells via regulating the MAPK signaling pathway. Biol. Pharm. Bull. 42 (11), 1783– 1788. 10.1248/bpb.b19-00053 31391347 · DOI
  60. Lu L. Hu W. Tian Z. Yuan D. Yi G. Zhou Y. (2019b). Developing natural products as potential anti-biofilm agents. Chin. Med. 14, 11. 10.1186/s13020-019-0232-2 30936939 PMC6425673 · DOI
  61. Luo L. Zhong Q. Guo S. Zhang C. Zhang Q. Zheng S. (2020a). Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE. Bioorg. Med. Chem. Lett. 30 (14), 127258. 10.1016/j.bmcl.2020.127258 32527558 PMC8570090 · DOI
  62. Luo Y. Song L. Wang X. Huang Y. Liu Y. Wang Q. (2020b). Uncovering the mechanisms of cryptotanshinone as a therapeutic agent against hepatocellular carcinoma. Front. Pharmacol. 11, 1264. 10.3389/fphar.2020.01264 32903546 PMC7438559 · DOI
  63. Lv C. Zeng H. W. Wang J. X. Yuan X. Zhang C. Fang T. (2018). The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell. Death Dis. 9, 165. 10.1038/s41419-017-0247-5 29416003 PMC5833361 · DOI
  64. Ma K. Zhang C. Huang M. Y. Guo Y. X. Hu G. Q. (2016). Crosstalk between Beclin-1-dependent autophagy and caspase-dependent apoptosis induced by tanshinone IIA in human osteosarcoma MG-63 cells. Oncol. Rep. 36 (4), 1807– 1818. 10.3892/or.2016.5003 27499329 PMC5022923 · DOI
  65. Mao S. Vincent M. Chen M. Zhang M. Hinek A. (2019). Exploration of multiple signaling pathways through which sodium tanshinone IIA sulfonate attenuates pathologic remodeling experimental infarction. Front. Pharmacol. 10, 779. 10.3389/fphar.2019.00779 31354493 PMC6639725 · DOI
  66. Miethke M. Pieroni M. Weber T. Bronstrup M. Hammann P. Halby L. (2021). Towards the sustainable discovery and development of new antibiotics. Nat. Rev. Chem. 5 (10), 726– 749. 10.1038/s41570-021-00313-1 34426795 PMC8374425 · DOI
  67. Mitchell P. Liew G. Gopinath B. Wong T. Y. (2018). Age-related macular degeneration. Lancet 392 (10153), 1147– 1159. 10.1016/s0140-6736(18)31550-2 30303083 · DOI
  68. Mizushima N. (2018). A brief history of autophagy from cell biology to physiology and disease. Nat. Cell. Biol. 20 (5), 521– 527. 10.1038/s41556-018-0092-5 29686264 · DOI · Paper page
  69. Musher D. M. Abers M. S. Corrales-Medina V. F. (2019). Acute infection and myocardial infarction. N. Engl. J. Med. 380 (2), 171– 176. 10.1056/NEJMra1808137 30625066 · DOI
  70. Neal R. D. Sun F. Emery J. D. Callister M. E. (2019). Lung cancer. BMJ-British Med. J. 365, l1725. 10.1136/bmj.l1725 31160279 · DOI
  71. Newman D. J. Cragg G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83 (3), 770– 803. 10.1021/acs.jnatprod.9b01285 32162523 · DOI
  72. Nixon R. A. (2013). The role of autophagy in neurodegenerative disease. Nat. Med. 19 (8), 983– 997. 10.1038/nm.3232 23921753 · DOI · Paper page
  73. Park I. J. Yang W. K. Nam S. H. Hong J. Yang K. R. Kim J. (2014). Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis 19 (4), 615– 628. 10.1007/s10495-013-0929-0 24173372 · DOI
  74. Parzych K. R. Klionsky D. J. (2014). An overview of autophagy: Morphology, mechanism, and regulation. Antioxid. Redox Signal. 20 (3), 460– 473. 10.1089/ars.2013.5371 23725295 PMC3894687 · DOI · Paper page
  75. Popova N. V. Juecker M. (2021). The role of mTOR signaling as a therapeutic target in cancer. Int. J. Mol. Sci. 22 (4), 1743. 10.3390/ijms22041743 33572326 PMC7916160 · DOI
  76. Qian J. Cao Y. Zhang J. Li L. Wu J. Wei G. (2020). Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway. Transl. Cancer Res. 9 (11), 6919– 6928. 10.21037/tcr-20-1963 35117300 PMC8797932 · DOI
  77. Qiu Y. Li C. Wang Q. Zeng X. Ji P. (2018). Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line. Cancer Med. 7 (2), 397– 407. 10.1002/cam4.1281 29316373 PMC5806115 · DOI
  78. Racanelli A. C. Kikkers S. A. Choi A. M. K. Cloonan S. M. (2018). Autophagy and inflammation in chronic respiratory disease. Autophagy 14 (2), 221– 232. 10.1080/15548627.2017.1389823 29130366 PMC5902194 · DOI · Paper page
  79. Rahal A. Kumar A. Singh V. Yadav B. Tiwari R. Chakraborty S. (2014). Oxidative stress, prooxidants, and antioxidants: The interplay. Biomed. Res. Int. 2014, 761264. 10.1155/2014/761264 24587990 PMC3920909 · DOI
  80. Ren J. Fu L. Nile S. H. Zhang J. Kai G. (2019). Salvia miltiorrhiza in treating cardiovascular diseases: A review on its pharmacological and clinical applications. Front. Pharmacol. 10, 753. 10.3389/fphar.2019.00753 31338034 PMC6626924 · DOI
  81. Scherlach K. Hertweck C. (2021). Mining and unearthing hidden biosynthetic potential. Nat. Commun. 12 (1), 3864. 10.1038/s41467-021-24133-5 34162873 PMC8222398 · DOI
  82. Shaito A. Duong Thi Bich T. Hoa Thi P. Thi Hieu Dung N. Hasan H. Halabi S. (2020). Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. Front. Pharmacol. 11, 422. 10.3389/fphar.2020.00422 32317975 PMC7155419 · DOI
  83. Shao M. Ye C. Bayliss G. Zhuang S. (2021). New insights into the effects of individual Chinese herbal medicines on chronic kidney disease. Front. Pharmacol. 12, 774414. 10.3389/fphar.2021.774414 34803715 PMC8599578 · DOI
  84. Shi K. Tian D. C. Li Z. G. Ducruet A. F. Lawton M. T. Shi F. D. (2019a). Global brain inflammation in stroke. Lancet Neurol. 18 (11), 1058– 1066. 10.1016/s1474-4422(19)30078-x 31296369 · DOI
  85. Shi M. J. Dong B. S. Yang W. N. Su S. B. Zhang H. (2019b). Preventive and therapeutic role of Tanshinone ⅡA in hepatology. Biomed. Pharmacother. 112, 108676. 10.1016/j.biopha.2019.108676 30797157 · DOI
  86. Su C. C. (2012). Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Exp. Ther. Med. 3 (3), 555– 559. 10.3892/etm.2011.441 22969929 PMC3438563 · DOI
  87. Su C. Y. Ming Q. L. Rahman K. Han T. Qin L. P. (2015). Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin. J. Nat. Med. 13 (3), 163– 182. 10.1016/s1875-5364(15)30002-9 25835361 · DOI
  88. Subedi L. Gaire B. P. (2021). Tanshinone IIA: A phytochemical as a promising drug candidate for neurodegenerative diseases. Pharmacol. Res. 169, 105661. 10.1016/j.phrs.2021.105661 33971269 · DOI
  89. Sun Y. Wu Y. Tang S. Liu H. Jiang Y. (2020). Sestrin proteins in cardiovascular disease. Clin. Chim. Acta 508, 43– 46. 10.1016/j.cca.2020.05.013 32407780 · DOI
  90. Tabas I. Bornfeldt K. E. (2016). Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res. 118 (4), 653– 667. 10.1161/circresaha.115.306256 26892964 PMC4762068 · DOI · Paper page
  91. Talib W. H. Alsayed A. R. Barakat M. Abu-Taha M. I. Mahmod A. I. (2021). Targeting drug chemo-resistance in cancer using natural products. Biomedicines 9 (10), 1353. 10.3390/biomedicines9101353 34680470 PMC8533186 · DOI
  92. Teng Q. X. Ashar Y. V. Gupta P. Gadee E. Fan Y. F. Reznik S. E. (2019). Revisiting mTOR inhibitors as anticancer agents. Drug Discov. Today 24 (10), 2086– 2095. 10.1016/j.drudis.2019.05.030 31173912 · DOI
  93. Tran M. Reddy P. H. (2021). Defective autophagy and mitophagy in aging and Alzheimer's disease. Front. Neurosci. 14, 612757. 10.3389/fnins.2020.612757 33488352 PMC7820371 · DOI
  94. Wang L. Hu T. Shen J. Zhang L. Chan R. L. Y. Lu L. (2015). Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer. Phytomedicine 22 (12), 1079– 1087. 10.1016/j.phymed.2015.08.009 26547530 · DOI
  95. Wang L. Xiong X. Zhang X. Ye Y. Jian Z. Gao W. (2020). Sodium tanshinone IIA sulfonate protects against cerebral ischemia-reperfusion injury by inhibiting autophagy and inflammation. Neuroscience 441, 46– 57. 10.1016/j.neuroscience.2020.05.054 32505745 · DOI
  96. White E. Mehnert J. M. Chan C. S. (2015). Autophagy, metabolism, and cancer. Clin. Cancer Res. 21 (22), 5037– 5046. 10.1158/1078-0432.Ccr-15-0490 26567363 PMC4646728 · DOI
  97. Wu T. Wang M. C. Jing L. Liu Z. Y. Guo H. Liu Y. (2015). Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des. devel. Ther. 9, 6421– 6431. 10.2147/DDDT.S95606 PMC4686226 26715839 · DOI
  98. Wu X. Liu L. Zheng Q. Ye H. Yang H. Hao H. (2022a). Dihydrotanshinone I preconditions myocardium against ischemic injury via PKM2 glutathionylation sensitive to ROS. Acta Pharm. Sin. B 5, 0318– 0333. 10.1016/j.apsb.2022.07.006 PMC9939318 36815040 · DOI
  99. Wu X. Xu Y. Liang Q. Yang X. Huang J. Wang J. (2022b). Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front. Pharmacol. 13, 875372. 10.3389/fphar.2022.875372 35614940 PMC9124774 · DOI
  100. Xiang H. Zhang J. Lin C. Zhang L. Liu B. Ouyang L. (2020). Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm. Sin. B 10 (4), 569– 581. 10.1016/j.apsb.2019.10.003 32322463 PMC7161711 · DOI
  101. Xie Q. Chen Y. Tan H. Liu B. Zheng L. L. Mu Y. (2021). Targeting autophagy with natural compounds in cancer: A renewed perspective from molecular mechanisms to targeted therapy. Front. Pharmacol. 12, 748149. 10.3389/fphar.2021.748149 34512368 PMC8427500 · DOI
  102. Xu Z. Chen L. Xiao Z. Zhu Y. Jiang H. Jin Y. (2018). Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomedicine 51, 58– 67. 10.1016/j.phymed.2018.05.012 30466628 · DOI
  103. Xu Z. Jiang H. Zhu Y. Wang H. Jiang J. Chen L. (2017). Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells. Chem. Biol. Interact. 273, 48– 55. 10.1016/j.cbi.2017.06.003 28600121 · DOI
  104. Yan R. Vassar R. (2014). Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13 (3), 319– 329. 10.1016/s1474-4422(13)70276-x 24556009 PMC4086426 · DOI
  105. Yen J. H. Huang S. T. Huang H. S. Fong Y. C. Wu Y. Y. Chiang J. H. (2018). HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells. Cell. Death Dis. 9, 1003. 10.1038/s41419-018-1016-9 30258193 PMC6158215 · DOI
  106. Yim W. W. Y. Mizushima N. (2020). Lysosome biology in autophagy. Cell. Discov. 6 (1), 6. 10.1038/s41421-020-0141-7 32047650 PMC7010707 · DOI
  107. Yuan H. Ma Q. Ye L. Piao G. (2016). The traditional medicine and modern medicine from natural products. Molecules 21 (5), 559. 10.3390/molecules21050559 27136524 PMC6273146 · DOI
  108. Yuan J. Dong X. Yap J. Hu J. (2020). The MAPK and AMPK signalings: Interplay and implication in targeted cancer therapy. J. Hematol. Oncol. 13 (1), 113. 10.1186/s13045-020-00949-4 32807225 PMC7433213 · DOI
  109. Yun C. W. Jeon J. Go G. Lee J. H. Lee S. H. (2021). The dual role of autophagy in cancer development and a therapeutic strategy for cancer by targeting autophagy. Int. J. Mol. Sci. 22 (1), 179. 10.3390/ijms22010179 PMC7795059 33375363 · DOI
  110. Zhang X. Wang Q. Wang X. Chen X. Shao M. Zhang Q. (2019). Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. Biomed. Pharmacother. 112, 108599. 10.1016/j.biopha.2019.108599 30798134 · DOI
  111. Zhang Y. Li W. Zhu S. Jundoria A. Li J. Yang H. (2012). Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. Biochem. Pharmacol. 84 (11), 1492– 1500. 10.1016/j.bcp.2012.09.015 23022229 PMC3491099 · DOI
  112. Zhang Y. Sowers J. R. Ren J. (2018). Targeting autophagy in obesity: From pathophysiology to management. Nat. Rev. Endocrinol. 14 (6), 356– 376. 10.1038/s41574-018-0009-1 29686432 · DOI · Paper page
  113. Zhang Z. Tang W. (2018). Drug metabolism in drug discovery and development. Acta Pharm. Sin. B 8 (5), 721– 732. 10.1016/j.apsb.2018.04.003 30245961 PMC6146880 · DOI
  114. Zheng L. Zhang Y. Liu G. Cheng S. Zhang G. An C. (2020). Tanshinone I regulates autophagic signaling via the activation of AMP-activated protein kinase in cancer cells. Anti-Cancer Drugs 31 (6), 601– 608. 10.1097/cad.0000000000000908 32011366 · DOI
  115. Zhou H. Zhao Y. Peng W. Han W. Wang Z. Ren X. (2021). Effect of sodium tanshinone IIA sulfonate injection on blood lipid in patients with coronary heart disease: A systematic review and meta-analysis of randomized clinical trials. Front. Cardiovasc. Med. 8, 770746. 10.3389/fcvm.2021.770746 34901229 PMC8652084 · DOI
  116. Zhou J. Jiang Y. Y. Chen H. Wu Y. C. Zhang L. (2020). Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell. Prolif. 53 (2), e12739. 10.1111/cpr.12739 31820522 PMC7046305 · DOI
  117. Zhou Z. Y. Zhao W. R. Zhang J. Chen X. L. Tang J. Y. (2019). Sodium tanshinone IIA sulfonate: A review of pharmacological activity and pharmacokinetics. Biomed. Pharmacother. 118, 109362. 10.1016/j.biopha.2019.109362 31545252 · DOI
  118. Zhu J. Liao S. Zhou L. Wan L. (2017a). Tanshinone IIA attenuates A(25-35)-induced spatial memory impairment via upregulating receptors for activated C kinase1 and inhibiting autophagy in hippocampus. J. Pharm. Pharmacol. 69 (2), 191– 201. 10.1111/jphp.12650 27882565 · DOI
  119. Zhu Y. Tang Q. Wang G. Han R. (2017b). Tanshinone IIA protects hippocampal neuronal cells from reactive oxygen species through changes in autophagy and activation of phosphatidylinositol 3-kinase, protein kinas B, and mechanistic target of rapamycin pathways. Curr. Neurovasc. Res. 14 (2), 132– 140. 10.2174/1567202614666170306105315 28260507 PMC5543574 · DOI
  120. Zou Z. Tao T. Li H. Zhu X. (2020). mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell. Biosci. 10 (1), 31. 10.1186/s13578-020-00396-1 32175074 PMC7063815 · DOI

Cited by

Sorted by citations

Authors
Wu, S., Zhao, K., Wang, J., Liu, N., Nie, K., Qi, L., & Xia, L.
Affiliations
  • Chengdu University of Traditional Chinese Medicine (CN)
  • Southwest Forestry University (CN)
Corresponding author
  • Qi, Luming
  • Xia, Lina
ORCID
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2023-01-12
Volume
13
Pages
1059360-1059360
ISSN
1663-9812 (ISSN-L)
DOI
10.3389/fphar.2022.1059360
PMC
PMC9877309
OpenAlex
W4315796648
Cited by
32
References
4
Citations by year
2026: 3 · 2025: 11 · 2024: 13 · 2023: 5
FWCI
1.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Analysis
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
tanshinones, autophagy, autophagy-related proteins, PI3K/AKT/mTOR pathway, Beclin-1, AMPK signaling, reactive oxygen species, neurodegenerative diseases, cardiovascular disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review